ArticleVaccines2021
Targeted COVID-19 Vaccination (TAV-COVID) Considering Limited Vaccination Capacities-An Agent-Based Modeling Evaluation.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Crises and complexity: how can we make health interventions succeed?Health policy and planning · 2025Article
- A unified framework for diagnostic test development and evaluation during outbreaks of emerging infections.Communications medicine · 2024Review
- Learning from the COVID-19 pandemic: A systematic review of mathematical vaccine prioritization models.Infectious Disease Modelling · 2024Review
- Learning from the COVID-19 pandemic: a systematic review of mathematical vaccine prioritization models.medRxiv : the preprint server for health sciences · 2024Article
- Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study.PharmacoEconomics · 2024Article
- Study of optimal vaccination strategies for early COVID-19 pandemic using an age-structured mathematical model: A case study of the USA.Mathematical biosciences and engineering : MBE · 2023Article
- Optimizing global COVID-19 vaccine allocation: An agent-based computational model of 148 countries.PLoS computational biology · 2022Article
- COVID-19 vaccine distribution planning using a congested queuing system-A real case from Australia.Transportation research. Part E, Logistics and transportation review · 2022Article
- Hamster models of COVID-19 pneumonia reviewed: How human can they be?Veterinary pathology · 2022Review
- You are only as safe as your riskiest contact: Effective COVID-19 vaccine distribution using local network information.Preventive medicine reports · 2022Article
- A 5-year look-back at the notification and management of vaccine supply shortages in Germany.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- On the role of data, statistics and decisions in a pandemic.Advances in statistical analysis : AStA : a journal of the German Statistical Society · 2022Article
- An iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply.PloS one · 2022Article
- Austria's Digital Vaccination Registry: Stakeholder Views and Implications for Governance.Vaccines · 2021Article
- Modelling COVID-19 dynamics and potential for herd immunity by vaccination in Austria, Luxembourg and Sweden.Journal of theoretical biology · 2021Article
- Efficiency in COVID-19 Vaccination Campaigns-A Comparison across Germany's Federal States.Vaccines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
(1) Background: The Austrian supply of COVID-19 vaccine is limited for now. We aim to provide evidence-based guidance to the authorities in order to minimize COVID-19-related hospitalizations and deaths in Austria. (2) Methods: We used a dynamic agent-based population model to compare different vaccination strategies targeted to the elderly (65 ≥ years), middle aged (45-64 years), younger (15-44 years), vulnerable (risk of severe disease due to comorbidities), and healthcare workers (HCW). First, outcomes were optimized for an initially available vaccine batch for 200,000 individuals. Second, stepwise optimization was performed deriving a prioritization sequence for 2.45 million individuals, maximizing the reduction in total hospitalizations and deaths compared to no vaccination. We considered sterilizing and non-sterilizing immunity, assuming a 70% effectiveness. (3) Results: Maximum reduction of hospitalizations and deaths was achieved by starting vaccination with the elderly and vulnerable followed by middle-aged, HCW, and younger individuals. Optimizations for vaccinating 2.45 million individuals yielded the same prioritization and avoided approximately one third of deaths and hospitalizations. Starting vaccination with HCW leads to slightly smaller reductions but maximizes occupational safety. (4) Conclusion: To minimize COVID-19-related hospitalizations and deaths, our study shows that elderly and vulnerable persons should be prioritized for vaccination until further vaccines are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.